NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Superior Plus Corp.
https://rdinvesting.com/news/?ticker=SPB.TO

Enbridge Inc.
https://rdinvesting.com/news/?ticker=ENB.TO

Fortis Inc.
https://rdinvesting.com/news/?ticker=FTS.TO

Global Water Resources, Inc.
https://rdinvesting.com/news/?ticker=GWR.TO

Superior Plus’ stock edged 0.47% higher Monday, to close the day at $12.75. The stock recorded a trading volume of 174,258 shares, which was below its three months average volume of 242,354 shares. In the last year, Superior Plus’ shares have traded in a range of 10.80 – 13.34. The share price has gained 18.06% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $12.01 is below its 200-day moving average of $12.10. Shares of Superior Plus have gained approximately 7.41 percent year-to-date.

Access RDI’s Superior Plus Corp. Research Report at:
https://rdinvesting.com/news/?ticker=SPB.TO

On Monday, shares of Enbridge recorded a trading volume of 2,246,419 shares, which was below the three months average volume of 3,208,855 shares. The stock ended the day 0.54% higher at 42.97. The stock is currently trading 25.59% below its 52-week high with a 52-week trading range of 42.00 – 57.75. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $46.10 is below its 200-day moving average of $48.58. Shares of the company are trading at a Price to Earnings ratio of 26.04. Shares of Enbridge have fallen approximately 12.59 percent year-to-date.

Access RDI’s Enbridge Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ENB.TO

Fortis’ stock edged 0.17% lower Monday, to close the day at $42.17. The stock recorded a trading volume of 717,756 shares, which was below its three months average volume of 1,086,203 shares. In the last year, Fortis’ shares have traded in a range of 39.38 – 48.73. The stock is currently trading 13.46% below its 52 week high. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $42.68 is below its 200-day moving average of $45.40. Shares of the company are trading at a Price to Earnings ratio of 18.26. Shares of Fortis have fallen approximately 8.54 percent year-to-date.

Access RDI’s Fortis Inc. Research Report at:
https://rdinvesting.com/news/?ticker=FTS.TO

On Monday, shares of Global Water Resources recorded a trading volume of 11,270 shares, which was above the three months average volume of 2,600 shares. The stock ended the day 0.54% lower at 10.99. The stock is currently trading 17.80% below its 52-week high with a 52-week trading range of 10.72 – 13.37. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $11.12 is below its 200-day moving average of $11.79. Shares of the company are trading at a Price to Earnings ratio of 157.00. Shares of Global Water Resources have fallen approximately 5.26 percent year-to-date.

Access RDI’s Global Water Resources, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=GWR.TO

Our Actionable Research on Superior Plus Corp. (TSX:SPB.TO), Enbridge Inc. (TSX:ENB.TO), Fortis Inc. (TSX:FTS.TO) and Global Water Resources, Inc. (TSX:GWR.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 490859

Mendelsohn Tells Entrepreneur Podcast Network Pursuit of Professional Passion and Philanthropy Are Cornerstone Values Instilled from Early Age at Company His Father Founded

WESLEY CHAPEL, FL / ACCESSWIRE / February 27, 2018 / Lane Mendelsohn, Vice President of Market Technologies, the leading provider of intermarket analysis software VantagePoint, describes coming of age in the world of artificial intelligence (AI) with his father at the helm, and provides insight on the company’s success in an interview on the Entrepreneur Podcast Network (EPN).

In the podcast, titled “Using Artificial Intelligence to Profitably Trade the Stock Market,” Mendelsohn says he started working alongside his father, CEO Louis Mendelsohn, at a very young age doing menial tasks. Two decades later and still working alongside his father – a globally renowned entrepreneur who pioneered applying AI and intermarket analysis to financial markets – the younger Mendelsohn reveals that diligently pursuing professional passion and giving back to the community are the keys to their success.

“Artificial intelligence is becoming mainstream now, but the truth is, we’ve been utilizing it since the late 1980s. VantagePoint Software can now predict stock movement for day traders with up to 86 percent accuracy, three days in advance,” Lane Mendelson said. “Because my father was passionate about this endeavor, we’re now helping our customers every day achieve financial freedom they never thought possible.”

During the podcast, Mendelsohn explains the company’s combined use of neural networks and ten years of intermarket historical trading data to give traders unprecedented predictability potential. VantagePoint Software recently predicted the Dow’s largest single-day point drop, which occurred Feb. 5, 2018, five days in advance. VantagePoint Software was also just rated “Highly Recommended” in a review by Your Trading Edge magazine.

“If you’re succeeding, it’s important to find ways to help other people,” Mendelsohn said. “We’re excited about partnering with organizations like The Shriners because they’re dedicated to community service and changing people’s lives for the better – a principle and standard we also set for ourselves. The goodness you spread will come back to you in multiples.”

A free VantagePoint demo is available at https://www.vantagepointsoftware.com/demo/ or by calling 800-732-5407.

About Market Technologies

Headquartered in Wesley Chapel, Fla., Market Technologies, creator of VantagePoint Software, is a pioneer and leader in trading software research and software development. VantagePoint forecasts Stocks, Futures, Forex, ETFs and cryptocurrencies with proven forecasting accuracy of up to 86%. Using artificial intelligence, VantagePoint’s patented Neural Network processes predict changes in market trend direction up to three days in advance, enabling traders to get in and out of trades at optimal times with greater confidence.

MEDIA CONTACT

Jen Aquilino
Communications Specialist
JenA@vantagepointsoftware.com

SOURCE: Market Technologies

ReleaseID: 490800

ENGLEWOOD CLIFFS, NJ / ACCESSWIRE / February 27, 2018 / Immune Pharmaceuticals, Inc. (NASDAQ; IMNP) (“Immune” or the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that Proposal 4 – Ratification of the Reverse Stock Split set forth in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on January 26, 2018 passed with shareholder approval.

The Company’s Annual Meeting of Stockholders, held on February 15, 2018, was convened on Proposals 1, 2, 3, 5 and 6, each as set forth in the Company’s Definitive Proxy Statement, with all such proposals having been ratified and approved in accordance with applicable law, rules and regulations. The Annual Meeting resumed with respect to Proposal 4 on February 23, 2018 and received the affirmative vote of approximately 81 percent of the shares of the Company’s common stock voted on this proposal, which represented a majority of the outstanding shares of common stock as of the Record Date (as such term defined).

Elliot Maza, President and CEO of Immune, commented, “We are grateful for the continued support of our shareholders. Our focus remains on executing on our corporate and clinical strategies with the goal of unlocking shareholder value in the near- and long-term.”

About Immune Pharmaceuticals, Inc.

Immune Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other diseases, including atopic dermatitis, immune and inflammatory hepatitis, and asthma.

Safe Harbor Statements Regarding Forward Looking Statements

The statements in this news release made by representatives of Immune relating to matters that are not historical facts, including without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Immune’s product candidates and the sufficiency of Immune’s cash and other capital resources, the continued development by Immune of bertilimumab or its determination to seek Orphan Drug designation for the pharmaceutical product of bertilimumab are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Immune’s ability to fund such efforts with or without partners. Immune undertakes no obligation to update any of these statements. In addition, there can be no assurance that Immune will successfully complete its anticipated corporate restructuring, filing of the Form 10, or consummation of the spin-off of Cytovia, or that Immune will be able to reduce expenses, capitalize on strategic alternatives, develop its assets, and generate value for shareholders. Immune may, at any time and for any reason until the proposed spin-off is complete, abandon the spin-off or modify its terms and conditions, or consider competing, alternate or complimentary transactions or offers by third parties at the discretion of Immune’s board of directors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Immune’s filings with the Securities and Exchange Commission, including those discussed in Immune’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and periodic reports filed on Form 8-K.

Investor Contact:

Jenene Thomas
Jenene Thomas Communications, LLC
(908) 938-1475
jtc@jtcir.com

SOURCE: Immune Pharmaceuticals Inc.

ReleaseID: 490841

Stock Monitor: Pandora Media Post Earnings Reporting

LONDON, UK / ACCESSWIRE / February 27, 2018 / Active-Investors.com has just released a free research report on Emmis Communications Corp. (NASDAQ: EMMS) (“Emmis”). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EMMS as the Company’s latest news hit the wire. On February 23, 2018, the Company announced that, as a part of its previously announced agreements to sell its St. Louis Radio Stations, it has entered into definitive agreements to sell St. Louis stations KSHE (94.7 FM) and The Point (KPNT, 105.7 FM) to Hubbard Radio for $45 million, and St. Louis stations KFTK (FM News Talk 97.1 FM) and NOW (KNOU, 96.3 FM) to Entercom Communications Corp. for $15 million. The transactions, according to the Company, are subject to FCC approval, closing adjustments, and pro-rations. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Pandora Media, Inc. (NYSE: P), which also belongs to the Services sector as the Company Emmis Communications. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=P

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Emmis Communications most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=EMMS

The Announcement

Emmis stated that the net proceeds of the transaction, after deducting transaction-related costs and estimated tax payments, would be used to repay term loans outstanding. According to Emmis, the St. Louis team has been an integral part of the Emmis radio station family since 1984; and Hubbard and Entercom are leading radio operators that would add great people and great brands to the St. Louis clusters. The transaction is expected to close in Q1 FY18, according to the Company.

Emmis is a leading media Company, primarily focused on radio broadcasting. The Company currently operates the 9th largest publicly-traded radio portfolio based on total listeners. The Company currently own 16 FM and 3 AM radio stations in New York, Los Angeles, St. Louis, Austin, and Indianapolis.

Company Growth Prospects

On January 09, 2018, Emmis, through its subsidiary, TagStation, LLC, which powered About NextRadio, announced an enhanced mobile radio solution – a hybrid radio application that would be available across select vehicle platforms on in-vehicle infotainment systems powered by Abaltas Weblink software platform. The Company added that the first iteration of the NextRadio for WebLink would be available in select aftermarket head units from JVCKENWOOD, and would begin shipping in early 2018. NextRadio for Weblink, according to the Company, enables drivers in any vehicle to have a rich in-dash AM/FM radio listening experience by connecting a smartphone to a compatible WebLink-enabled car head unit, which requires minimal smartphone data and battery usage.

Under the terms of the agreement, Abalta Technologies, a leading provider of technology and infotainment solutions, would bring all the pieces of the connected car experience on one single platform. By leveraging the Company’s WebLink solution, both carmakers and suppliers could bridge the gap between consumer smartphones and IVI systems, delivering car owners access to their favorite apps in an easy-to-use, customizable and platform-agnostic environment.

Additionally, on January 09, 2018, TagStation announced that Samsung, the largest Android handset maker in the world, was the latest device OEM to continue its support for NextRadio by unlocking the FM chip in upcoming smartphone models in the US and Canada.

Stock Performance Snapshot

February 26, 2018 – At Monday’s closing bell, Emmis Communications’ stock climbed 3.33%, ending the trading session at $4.03.

Volume traded for the day: 46.96 thousand shares, which was above the 3-month average volume of 22.89 thousand shares.

Stock performance in the last month – up 28.34%; previous three-month period – up 11.57%; past twelve-month period – up 38.01%; and year-to-date – up 14.49%

After yesterday’s close, Emmis Communications’ market cap was at $43.73 million.

Price to Earnings (P/E) ratio was at 0.82.

The stock is part of the Services sector, categorized under the Broadcasting – Radio industry. This sector was up 0.7% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 490849

Stock Monitor: James River Group Holdings Post Earnings Reporting

LONDON, UK / ACCESSWIRE / February 27, 2018 / Active-Investors.com has just released a free earnings report on Everest Re Group, Ltd (NYSE: RE) (“Everest”). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=RE. Everest reported its fourth quarter fiscal 2017 operating and financial results on February 05, 2018. The reinsurance Company topped premium and earnings estimates. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for James River Group Holdings, Ltd. (NASDAQ: JRVR), which also belongs to the Financial sector as the Company Everest Re Group. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=JRVR

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Everest Re Group most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=RE

Earnings Highlights and Summary

For Q4 2017, Everest reported revenue advanced 16.1% to $1.87 billion compared to $1.61 billion in Q4 2016.

For full year (FY) 2017, Everest recorded revenue of $6.61 billion compared to $5.79 billion in FY16.

Everest reported net income of $571.0 million, or $13.85 per diluted share, in Q4 2017 compared to net income of $373.6 million, or $9.08 per diluted share, for Q4 2016. The Company’s after-tax operating income, excluding realized capital gains and losses and the tax charge related to the enactment of the Tax Cuts and Jobs Act of 2017 (TCJA), was $556.0 million, or $13.48 per diluted share, compared to after-tax operating income of $363.4 million, or $8.83 per diluted share, for the year ago same period. Everest’s earnings beat Wall Street’s estimates of $5.24 per share.

For FY17, Everest’s net income was $469.0 million, or $11.36 per diluted common share, compared to $996.3 million, or $23.68 per diluted common share, for FY16. The Company’s after-tax operating income, excluding realized capital gains and losses and the tax charge related to the enactment of the TCJA, was $375.4 million, or $9.10 per diluted common share, for FY17 compared to $993.5 million, or $23.61 per diluted common share, for FY16.

Operating highlights

During Q4 2017, Everest’s gross written premiums were $1.9 billion, reflecting an increase of 26% on a y-o-y basis. The Company’s premiums earned totaled $1.66 billion, ahead of analysts’ estimates of $8.31 million.

For FY17, Everest’s gross written premiums grew 19% to $7.2 billion. The Company’s worldwide reinsurance premiums advanced 17% on a y-o-y basis, while direct insurance premiums were up 15% for FY17.

Everest’s combined ratio was 70.0% for Q4 2017 compared to 82.1% for Q4 2016. The reported quarter benefitted from net prior year reserve releases of $262.1 million and a net reduction to prior period catastrophe loss estimates of $132.7 million, offset by $161.5 million for catastrophe losses that occurred in Q4 2017, including both the Northern and Southern California wildfires.

Everest posted combined ratio of 103.5% for FY17 compared to 87.0% for FY16. For FY17, catastrophe losses, net of reinstatement premiums, totaled $1.3 billion. Excluding catastrophe losses, reinstatement premiums and favorable prior year loss development, Everest’s FY17 attritional combined ratio was 85.0% compared to 85.5% for FY16.

Everest’s net investment income amounted to $149.1 million for Q4 2017 and $542.9 million for FY17. The Company’s net after-tax realized capital gains totaled $23.2 million in the reported quarter.

Cash Matters

Everest’s cash flow from operations was $118.5 million for Q4 2017 compared to $422.9 million for Q4 2016. The Company’s FY17 cash flow from operations was $1.2 billion compared to $1.4 billion for FY16.

For FY17, Everest’s after-tax operating income return on average adjusted shareholders’ equity was 4.6%. During the reported quarter and full year 2017, the Company purchased 236,493 shares for a total cost of $50 million. The repurchases were made pursuant to a share repurchase authorization, provided by the Company’s Board of Directors, under which there remains 1.8 million shares.

Everest’s shareholders’ equity ended FY17 at $8.4 billion. The Company’s book value per share increased 4% from $197.45 at year-end 2016 to $204.95 at December 31, 2017.

Stock Performance Snapshot

February 26, 2018 – At Monday’s closing bell, Everest Re’s stock slightly declined 0.54%, ending the trading session at $241.63.

Volume traded for the day: 336.00 thousand shares.

Stock performance in the last month – up 4.63%; previous three-month period – up 10.21%; past twelve-month period – up 2.81%; and year-to-date – up 9.21%

After yesterday’s close, Everest Re’s market cap was at $9.78 billion.

Price to Earnings (P/E) ratio was at 21.30.

The stock has a dividend yield of 2.15%.

The stock is part of the Financial sector, categorized under the Property & Casualty Insurance industry. This sector was up 1.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 490850

Stock Monitor: Zix Corp. Post Earnings Reporting

LONDON, UK / ACCESSWIRE / February 27, 2018 / Active-Investors.com has just released a free earnings report on Fortinet, Inc. (NASDAQ: FTNT). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=FTNT. The Company reported its fourth quarter fiscal 2017 operating and financial results on February 05, 2018. The network security Company outperformed top- and bottom-line expectations, and provided guidance for the upcoming quarter and fiscal year. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Zix Corporation (NASDAQ: ZIX), which also belongs to the Technology sector as the Company Fortinet. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=ZIX

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Fortinet most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=FTNT

Earnings Highlights and Summary

For Q4 2017, Fortinet’s total revenues advanced 15% to $416.7 million compared to $362.8 million in Q4 2016. The Company’s revenue numbers topped analysts’ estimates of $408.6 million.

During Q4 2017, Fortinet’s GAAP operating income was $42.2 million, representing a GAAP operating margin of 10%, compared to a GAAP operating income of $45.2 million, or a GAAP operating margin of 12%, for Q4 2016. For Q4 2017, Fortinet’s non-GAAP operating income was $78.7 million, reflecting a non-GAAP operating margin of 19%, versus a non-GAAP operating income of $81.1 million, or a non-GAAP operating margin of 22%, for Q4 2016.

For Q4 2017, Fortinet posted a GAAP net loss of $29.0 million compared to a GAAP net income of $25.2 million for Q4 2016. The Company’s GAAP diluted net loss was $0.17 per share for the reported quarter, based on 171.5 million diluted weighted-average shares outstanding, compared to a GAAP diluted net income of $0.14 per share for the prior year’s same quarter, based on 176.7 million diluted weighted-average shares outstanding. Fortinet’s Q4 2017 results were impacted by a one-time tax expense of $63.0 million, or $0.36 per share, resulting from the Tax Cuts and Jobs Act 2017 (TCJA) signed into law in December 2017.

Fortinet’s non-GAAP net income was $55.5 million, or $0.32 per share, for Q4 2017 compared to a non-GAAP net income of $53.2 million, or $0.30 per share, for Q4 2016. The Company’s earnings beat Wall Street’s estimates of $0.29 per share.

For the full year FY17, Fortinet’s total revenues advanced 17% to $1.49 billion compared to $1.28 billion in FY16.

For FY17, Fortinet’s GAAP net income was $31.4 million, or $0.18 per share, compared to a GAAP net income of $32.2 million, or $0.18 per share, for FY16. The Company’s net income in FY17 was impacted by a one-time tax expense of $63.0 million, or $0.35 per share, resulting from the TCJA. Fortinet’s non-GAAP net income was $184.7 million, or $1.04 per share, for FY17 compared to a non-GAAP net income of $129.5 million, or $0.73 per share, for FY16.

Operating Results

During Q4 2017, Fortinet’s Product revenues grew 2% to $162.1 million compared to $158.9 million in Q4 2016. The Company’s Service revenues were $254.6 million, reflecting an increase of 25% versus $203.9 million in the year earlier comparable quarter.

Fortinet’s total billings jumped 15% to $534.0 million for Q4 2017 compared to $463.4 million in Q4 2016.

Fortinet’s total deferred revenues were $1.34 billion as of December 31, 2017, reflecting an increase of 29% compared to $1.04 billion as of December 31, 2016.

Cash Matters

As of December 31, 2017, Fortinet’s cash, cash equivalents, and investments were $1.35 billion compared to $1.52 billion as of September 30, 2017. In Q4 2017, the Company’s cash flow from operations was $157.5 million compared to $101.0 million in Q4 2016, while free cash flow was $143.9 million compared to $84.2 million in the year earlier corresponding quarter.

In FY17, Fortinet’s cash flow from operations was $594.4 million compared to $345.7 million in FY16. The Company’s free cash flow was $459.1 million in FY17 compared to $278.5 million in FY16. In FY17, Fortinet used $107.2 million for real estate purchases for its Canada and Sunnyvale offices.

During Q4 2017, Fortinet repurchased 7.9 million shares of its common stock for a total purchase price of $322.4 million. During FY17, the Company repurchased 11.2 million shares of its common stock for a total purchase price of $446.3 million.

Guidance

For the first quarter of FY18, Fortinet is forecasting revenues to be in the range of $387.0 million to $393.0 million, and billings to be in the band of $449.0 million to $457.0 million. The Company is estimating non-GAAP operating margin to be in the range of 12% to 13%, and non-GAAP earnings per diluted share to be in the band of $0.21 to $0.22.

For the full fiscal year 2018, Fortinet is projecting revenues to be in the range of $1.695 billion to $1.715 billion, and billings to be in the band of $2.03 billion to $2.05 billion. The Company is expecting non-GAAP operating margin to be in the range of 17.7% to 18%, and non-GAAP earnings per diluted share to be in the band of $1.30 to $1.32.

Stock Performance Snapshot

February 26, 2018 – At Monday’s closing bell, Fortinet’s stock was marginally up 0.90%, ending the trading session at $50.32.

Volume traded for the day: 1.11 million shares.

Stock performance in the last month – up 10.81%; previous three-month period – up 20.47%; past twelve-month period – up 35.45%; and year-to-date – up 15.18%

After yesterday’s close, Fortinet’s market cap was at $8.63 billion.

Price to Earnings (P/E) ratio was at 299.52.

The stock is part of the Technology sector, categorized under the Application Software industry. This sector was up 1.2% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 490851

– Wearable healthcare technology hasn’t translated into gains for these companies and their stocks yet, despite hype around the potential for health tracking.
– Medical-grade products are producing massively for medical device companies, meanwhile, with medical device ETF climbing 300% over last few years as tech has advanced.
– BTCY is a standout, despite being undiscovered by public market investors. Newly FDA-cleared device about to be launch commercially, and tiny valuation could soar as first sales emerge in hot remote cardiac monitoring market. Similar BEAT has been a big winner, up 1300% in give years.

NEW YORK, NY / ACCESSWIRE / February 27, 2018 / The future of prevention in healthcare is small, mobile, and wearable. Just ask health insurance companies, which for the last year have been adopting programs that allow their members to receive discounts on their premiums for wearing fitness trackers – an incentive to get active each day. After all, heart disease and stroke are still the leading causes of death and disability globally, killing more than 17 million people a year, and they have been for nearly 20 years. Fitbit (NYSE:FIT) was an early mover with their wearable fitness trackers, partnering with UnitedHealth Group (UNH) and Qualcomm (NASDAQ:QCOM), as well as Blue Cross Blue Shield.

The effort to use smaller, smarter and connected technology to improve health outcomes is a noble one, but it hasn’t translated into gains for the maker of smart watches and fitness trackers. Shares in Fitbit have lost more than 50% of their value in the last two years, despite deepening their reach into healthcare, even partnering with Medtronic PLC (MDT).

So, who is benefiting from sleeker, cheaper technology to keep consumers – and moreso, patients – monitored and healthy? True medical device makers, especially those that can get physicians onboard and prescribing a new class of mobile telemetry devices. Penetrating the gatekeepers of the healthcare industry – doctors AND payors like insurance companies and medicare/medicaid – has been no easy task for tech companies unfamiliar with the healthcare landscape.

This is where the real money is being made – in medical devices that get prescribed and used by physicians and healthcare providers, which is why recent activity at Biotricity (BTCY) makes this little company so compelling. Biotricity just received U.S. Food and Drug Administration clearance for their unique remote cardiac monitoring device, called Bioflux. With this device launching imminently into a $22 billion market annually, a clear path for physician uptake, and peers trading at gargantuan market capitalizations with achievable revenues, BTCY could be a top small-cap healthcare name in 2018 worth as much as 200-300% more with 2018 events.

Despite The Hype, Wearables Not Translating Yet

As technology has gotten cheaper and smaller, so too has the potential for mobile and wearable devices to change how we do healthcare in a drastic way. Fitbit has been at the forefront of this move, with newer versions of their fitness tracking devices including more and more technology; heart rate sensors are almost ubiquitous. Fitbit now has partnerships with major insurance companies to get their clients out and active, and the company has even partnered with DexCom, Inc. (DXCM) on diabetes focused products.

Still, consumer-directed wearables have been remarkably slow to impact how we DO healthcare, and the promised improved outcomes have been slow to materialize in any empirical form.

Despite much hype around Apple (AAPL), Samsung and so many tech companies getting into the healthcare game, physicians aren’t much for these consumer products. According to the 2017 Physicians Practice Technology Survey, only 5% of physician respondents say they use technology that monitors their patients’ health status, like fitness or sleep trackers.

The adoption rate is shockingly low because the data just isn’t that useful! According to Dan Ledger, founder of the research and advisory firm Path Collaborative, “A lot of the consumer wearables are living outside the sphere of healthcare. Doctors might say, ‘You should get a Fitbit,’ and that’s where the conversations end. They don’t say, ‘Bring me the data.'”

Doctors just aren’t getting useful insights from wearables…yet.

Small, Medical-Grade Remote Monitoring Companies Are A Runaway Success

Meanwhile, the money is being made in medical-grade devices, which institutions and doctors incorporate right into their procedure and diagnostic process. Newer, faster, and more connected devices are being used hand over first directly in the treatment setting. In places where doctors make the decisions and can use a monitoring technology directly in their practice, you can bet money is being made. Distinct CPT codes already allow doctors to bill payors like insurance and Medicare for very specific products, like for the “collection and interpretation of physiologic data…digitally stored and/or transmitted by the patient and/or caregiver…”

The rally in medical device stocks is evidence of this, with the iShares US Medical Devices ETF (IHI) climbing almost three-fold in five years!

One of the fastest-growing and largest use cases is in heart monitoring, where newer devices gather and transmit needed information directly to a care team for a diagnosis or monitoring after a hospital stay. According to the Centers for Disease Control and Prevention, 11 million patients in the United States have a heart rhythm disorder or arrhythmia. Diagnosis relies on tests such as ECGs (electrocardiograms) to determine the severity of the disorder. Initially, this includes an in-hospital ECG, but arrhythmias can be sporadic, and keeping patients in the hospital hooked to an ECG is unrealistically expensive and inconvenient for days or weeks at a time.

The most recent advancement in cardiac monitoring is Continual Mobile Cardiac Telemetry (MCT), consisting of around-the-clock patient heart monitoring through small unobtrusive leads on the chest and a small, phone-like device that the patient carries with them. The device transmits the data via cell signal to remote monitoring centers, or can be periodically dumped or sent back to a data center. The MCT space has grown with improved technology, similar to wearables, and doctors are increasingly turning to simple Remote devices as opposed to older, bulkier devices that require a carrying case.

Smaller upstarts have been huge beneficiaries. Biotelemetry’s (BEAT) sole focus is remote cardiac monitoring, and since re-positioning the business a few years ago, is now doing $287 million in revenue from their cardiac monitoring services business. The company is valued at $1.1 billion in market capitalization, and has climbed from $2.50 to $35 in just five years – a 1300% return.

IRhythym (IRTC) did $99 million last year with their sole product, the Zio Device, just two years since their IPO. IRTC is up almost 200% and is loved by Wall Street, with a $1.2 billion valuation based on the growth opportunity in cardiac monitoring.

Biotricity (BTCY) just received FDA clearance for their first proprietary Mobile Cardiac Telemetry (MCT) system, called Bioflux MCT, making this only one of a handful of cleared mobile monitoring devices.

Bioflux was approved two months ago in December of 2017, and it’s arguably a superior product to alternatives on the market. Bioflux is a small monitoring device that can provide up to 30 days of near real-time ECG monitoring and allows physicians to understand a patient’s early symptoms of arrhythmia, to diagnose and provide proper treatment. Where other monitors require “dumping” their data to providers periodically or at the end of the evaluation period (like IRTC’s Zio), Bioflux sends the data in real-time via cellular connection to remote monitoring facilities.

Launch Underway, BTCY Could Be Worth 200 to 300% More With Execution

The Bioflux launch is just getting underway and 2018 could be a banner year for BTCY as this takes off. The European company LifeWatch AG was acquired for almost $300 million last year, not long after their own MCT was approved, and it’s now a part of Biotelemetry’s cardiac monitoring portfolio. Quality technology like Bioflux may also not last long in a standalone company, but even nominal sales in the coming months could be transformative to BTCY.

The company is still undiscovered despite the tremendous upside potential at an $85 million market valuation. IRTC’s $99 million in 2017 sales translates to a 15X Price-to-Sales multiple – even $20 million in sales for Bioflux in the coming year could justify a 250% move higher for BTCY! Cardiac monitoring was a $22.2 billion market globally in 2016 and is expected to reach $28 billion by 2021, thus the company doesn’t have to peel off much market share in order to justify a much higher valuation.

With micro-cap stocks, the investment risk is always higher, and the company may never be able to compete against bigger companies despite the strengths of Bioflux. Biotricity should be considered a high-risk, high-reward opportunity, as an investment could be worth nothing at all if the company can’t execute on their product launch.

Another facet that has yet to be noticed by the public markets is the company’s goal of bringing additional remote monitoring technology to market – they bill themselves as a technology company, and R&D initiatives could bring new products to light in 2018. The company is already working on a second generation Bioflux device that incorporates AI right into the platform – another potential catalyst to send BTCY higher in 2018.

About One Equity Stocks

One Equity Stocks is a leading provider of research on publicly traded emerging growth companies. Our team is comprised of sophisticated financial professionals that strive to find the companies and management teams that will outperform the market and deliver investment returns to our subscribers. We are not a licensed broker-dealer and do not publish investment advice and remind readers that investing involves considerable risk. One Equity Stocks encourages all readers to carefully review the SEC filings of any issuers we cover and consult with an investment professional before making any investment decisions. One Equity Stocks is a for-profit business and is usually compensated for coverage of issuers. In the case of BTCY, we are reimbursed for actual costs of this distribution and have received 100,000 shares of restricted stock for Business Development, Capital Markets and Research Services. We will likely receive an additional 20,000 shares of BTCY in the future. Please contact us at info@investorclick.net for additional information or to subscribe to our intelligence service.

SOURCE: One Equity Stocks

ReleaseID: 490873

NEW YORK, NY / ACCESSWIRE / February 27, 2018 / HealthSouth Corporation (NYSE: EHC) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 9:00 AM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/company/1778

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company’s profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 490432

NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 9:30 AM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/company/1630

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company’s profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 490438